Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 393

1.

A Guide for Applying to Addiction Psychiatry Fellowship.

Rakocevic DB, DeJong SM, Saxon AJ, Renner JA Jr, Schwartz AC.

Acad Psychiatry. 2019 Nov 26. doi: 10.1007/s40596-019-01144-5. [Epub ahead of print] No abstract available.

PMID:
31773502
2.

Inhibition of Allergic Reactivity through Targeting FcεRI-Bound IgE with Humanized Low-Affinity Antibodies.

Zhang K, Elias M, Zhang H, Liu J, Kepley C, Bai Y, Metcalfe DD, Schiller Z, Wang Y, Saxon A.

J Immunol. 2019 Dec 1;203(11):2777-2790. doi: 10.4049/jimmunol.1900112. Epub 2019 Oct 21.

PMID:
31636239
3.

Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder.

Evans EA, Yoo C, Huang D, Saxon AJ, Hser YI.

J Subst Abuse Treat. 2019 Nov;106:19-28. doi: 10.1016/j.jsat.2019.08.002. Epub 2019 Aug 7.

PMID:
31540607
4.

Effect of a Care Management Intervention on 12-Month Drinking Outcomes Among Patients With and Without DSM-IV Alcohol Dependence at Baseline.

Williams EC, Bobb JF, Lee AK, Ludman EJ, Richards JE, Hawkins EJ, Merrill JO, Saxon AJ, Lapham GT, Matson TE, Chavez LJ, Caldeiro R, Greenberg DM, Kivlahan DR, Bradley KA.

J Gen Intern Med. 2019 Dec 10. doi: 10.1007/s11606-019-05261-7. [Epub ahead of print]

PMID:
31432438
5.

New Coprescription of Opioids and Benzodiazepines and Mortality Among Veterans Affairs Patients With Posttraumatic Stress Disorder.

Hawkins EJ, Goldberg SB, Malte CA, Saxon AJ.

J Clin Psychiatry. 2019 Jul 9;80(4). pii: 18m12689. doi: 10.4088/JCP.18m12689.

PMID:
31294933
6.

The Next Stage of Buprenorphine Care for Opioid Use Disorder.

Duncan MH, Ratzliff AD, Powers DM, Banta-Green CJ, Saxon AJ.

Ann Intern Med. 2019 Jun 4;170(11):820-821. doi: 10.7326/L19-0144. No abstract available.

PMID:
31158865
7.

Medications to treat cocaine use disorders: current options.

Buchholz J, Saxon AJ.

Curr Opin Psychiatry. 2019 Jul;32(4):275-281. doi: 10.1097/YCO.0000000000000518.

PMID:
31008728
8.

Harm reduction treatment for smoking (HaRT-S): findings from a single-arm pilot study with smokers experiencing chronic homelessness.

Collins SE, Nelson LA, Stanton J, Mayberry N, Ubay T, Taylor EM, Hoffmann G, Goldstein SC, Saxon AJ, Malone DK, Clifasefi SL, Okuyemi K; HaRT-S Community Advisory Board.

Subst Abus. 2019;40(2):229-239. doi: 10.1080/08897077.2019.1572049. Epub 2019 Mar 29.

PMID:
30924732
9.

Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence.

Godersky ME, Saxon AJ, Merrill JO, Samet JH, Simoni JM, Tsui JI.

Addict Sci Clin Pract. 2019 Mar 13;14(1):11. doi: 10.1186/s13722-019-0139-3.

10.

Prazosin for Alcohol Use Disorder: Response to Kleinman and Ostacher.

Simpson TL, Saxon AJ, Raskind M.

Am J Psychiatry. 2019 Feb 1;176(2):165-166. doi: 10.1176/appi.ajp.2018.18101143r. No abstract available.

PMID:
30704279
11.

Use of Prolonged Exposure and Sertraline in the Treatment of Posttraumatic Stress Disorder for Veterans.

Kaysen DL, Bedard-Gilligan MA, Saxon AJ.

JAMA Psychiatry. 2019 Feb 1;76(2):109-110. doi: 10.1001/jamapsychiatry.2018.3410. No abstract available.

PMID:
30516796
12.

Escalating Opioid Dose Is Associated With Mortality: A Comparison of Patients With and Without Opioid Use Disorder.

Hser YI, Saxon AJ, Mooney LJ, Miotto K, Zhu Y, Yoo CK, Liang D, Huang D, Bell DS.

J Addict Med. 2019 Jan/Feb;13(1):41-46. doi: 10.1097/ADM.0000000000000458.

PMID:
30418260
13.

Double-Blind Randomized Clinical Trial of Prazosin for Alcohol Use Disorder.

Simpson TL, Saxon AJ, Stappenbeck C, Malte CA, Lyons R, Tell D, Millard SP, Raskind M.

Am J Psychiatry. 2018 Dec 1;175(12):1216-1224. doi: 10.1176/appi.ajp.2018.17080913. Epub 2018 Aug 29.

14.

Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial.

Zhu Y, Evans EA, Mooney LJ, Saxon AJ, Kelleghan A, Yoo C, Hser YI.

J Neuroimmune Pharmacol. 2018 Dec;13(4):488-497. doi: 10.1007/s11481-018-9801-x. Epub 2018 Aug 9.

15.

The Unmet Challenges of Co-Occurring Alcohol and Opioid Use.

Saxon AJ.

Alcohol Clin Exp Res. 2018 May 30. doi: 10.1111/acer.13797. [Epub ahead of print] No abstract available.

PMID:
29846946
16.

The Role of Cannabis Legalization in the Opioid Crisis.

Hill KP, Saxon AJ.

JAMA Intern Med. 2018 May 1;178(5):679-680. doi: 10.1001/jamainternmed.2018.0254. No abstract available.

PMID:
29610836
17.

Alcohol-Related Nurse Care Management in Primary Care: A Randomized Clinical Trial.

Bradley KA, Bobb JF, Ludman EJ, Chavez LJ, Saxon AJ, Merrill JO, Williams EC, Hawkins EJ, Caldeiro RM, Achtmeyer CE, Greenberg DM, Lapham GT, Richards JE, Lee AK, Kivlahan DR.

JAMA Intern Med. 2018 May 1;178(5):613-621. doi: 10.1001/jamainternmed.2018.0388.

18.

Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry.

Saxon AJ, Akerman SC, Liu CC, Sullivan MA, Silverman BL, Vocci FJ.

Addiction. 2018 Aug;113(8):1477-1487. doi: 10.1111/add.14199. Epub 2018 Apr 1.

PMID:
29493836
19.

Electronic Medical Record Alert Associated With Reduced Opioid and Benzodiazepine Coprescribing in High-risk Veteran Patients.

Malte CA, Berger D, Saxon AJ, Hagedorn HJ, Achtmeyer CE, Mariano AJ, Hawkins EJ.

Med Care. 2018 Feb;56(2):171-178. doi: 10.1097/MLR.0000000000000861.

PMID:
29287034
20.

Temperature fluctuations during development reduce male fitness and may limit adaptive potential in tropical rainforest Drosophila.

Saxon AD, O'Brien EK, Bridle JR.

J Evol Biol. 2018 Mar;31(3):405-415. doi: 10.1111/jeb.13231. Epub 2018 Jan 30.

PMID:
29282784
21.

A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal.

Gorodetzky CW, Walsh SL, Martin PR, Saxon AJ, Gullo KL, Biswas K.

Drug Alcohol Depend. 2017 Jul 1;176:79-88. doi: 10.1016/j.drugalcdep.2017.02.020. Epub 2017 May 10.

22.

Patient-centered primary care for adults at high risk for AUDs: the Choosing Healthier Drinking Options In primary CarE (CHOICE) trial.

Bradley KA, Ludman EJ, Chavez LJ, Bobb JF, Ruedebusch SJ, Achtmeyer CE, Merrill JO, Saxon AJ, Caldeiro RM, Greenberg DM, Lee AK, Richards JE, Thomas RM, Matson TE, Williams EC, Hawkins E, Lapham G, Kivlahan DR.

Addict Sci Clin Pract. 2017 May 17;12(1):15. doi: 10.1186/s13722-017-0080-2.

23.

Providing intensive addiction/housing case management to homeless veterans enrolled in addictions treatment: A randomized controlled trial.

Malte CA, Cox K, Saxon AJ.

Psychol Addict Behav. 2017 May;31(3):231-241. doi: 10.1037/adb0000273.

PMID:
28481614
24.

Characteristics and service utilization of homeless veterans entering VA substance use treatment.

Cox KB, Malte CA, Saxon AJ.

Psychol Serv. 2017 May;14(2):208-213. doi: 10.1037/ser0000133.

PMID:
28481606
25.

Chronic pain among patients with opioid use disorder: Results from electronic health records data.

Hser YI, Mooney LJ, Saxon AJ, Miotto K, Bell DS, Huang D.

J Subst Abuse Treat. 2017 Jun;77:26-30. doi: 10.1016/j.jsat.2017.03.006. Epub 2017 Mar 9.

26.

High Mortality Among Patients With Opioid Use Disorder in a Large Healthcare System.

Hser YI, Mooney LJ, Saxon AJ, Miotto K, Bell DS, Zhu Y, Liang D, Huang D.

J Addict Med. 2017 Jul/Aug;11(4):315-319. doi: 10.1097/ADM.0000000000000312.

27.

Blocking Allergic Reaction through Targeting Surface-Bound IgE with Low-Affinity Anti-IgE Antibodies.

Zhang K, Liu J, Truong T, Zukin E, Chen W, Saxon A.

J Immunol. 2017 May 15;198(10):3823-3834. doi: 10.4049/jimmunol.1602022. Epub 2017 Apr 10.

28.

Causes of death and expected years of life lost among treated opioid-dependent individuals in the United States and Taiwan.

Chang KC, Wang JD, Saxon A, Matthews AG, Woody G, Hser YI.

Int J Drug Policy. 2017 May;43:1-6. doi: 10.1016/j.drugpo.2016.12.003. Epub 2017 Feb 1.

29.

Enhanced Prophylactic and Therapeutic Effects of Polylysine-Modified Ara h 2 DNA Vaccine in a Mouse Model of Peanut Allergy.

Zhu Z, Yu J, Niu Y, Sun S, Liu Y, Saxon A, Zhang K, Li W.

Int Arch Allergy Immunol. 2016;171(3-4):241-250. doi: 10.1159/000453264. Epub 2017 Jan 4.

30.

Methadone "callbacks" within a veterans affairs opioid treatment program: Detecting methadone misuse.

Cotton AJ, Shipley LJ, Glynn LH, Tracy J, Saxon AJ.

Am J Addict. 2017 Jan;26(1):50-52. doi: 10.1111/ajad.12479.

PMID:
28005315
31.

A polymorphism in the OPRM1 3'-untranslated region is associated with methadone efficacy in treating opioid dependence.

Crist RC, Doyle GA, Nelson EC, Degenhardt L, Martin NG, Montgomery GW, Saxon AJ, Ling W, Berrettini WH.

Pharmacogenomics J. 2018 Jan;18(1):173-179. doi: 10.1038/tpj.2016.89. Epub 2016 Dec 13.

32.

Distinctive Trajectories of Opioid Use Over an Extended Follow-up of Patients in a Multisite Trial on Buprenorphine + Naloxone and Methadone.

Hser YI, Huang D, Saxon AJ, Woody G, Moskowitz AL, Matthews AG, Ling W.

J Addict Med. 2017 Jan/Feb;11(1):63-69. doi: 10.1097/ADM.0000000000000274.

33.

Survey of Primary Care and Mental Health Prescribers' Perspectives on Reducing Opioid and Benzodiazepine Co-Prescribing Among Veterans.

Hawkins EJ, Malte CA, Hagedorn HJ, Berger D, Frank A, Lott A, Achtmeyer CE, Mariano AJ, Saxon AJ.

Pain Med. 2017 Mar 1;18(3):454-467. doi: 10.1093/pm/pnw140.

PMID:
27558857
34.

A narrative review: The effects of opioids on sleep disordered breathing in chronic pain patients and methadone maintained patients.

Hassamal S, Miotto K, Wang T, Saxon AJ.

Am J Addict. 2016 Sep;25(6):452-65. doi: 10.1111/ajad.12424. Review.

PMID:
27554389
35.

Prevalence of Alcohol Misuse and Follow-Up Care in a National Sample of OEF/OIF VA Patients With and Without TBI.

Grossbard J, Malte CA, Lapham G, Pagulayan K, Turner AP, Rubinsky AD, Bradley KA, Saxon AJ, Hawkins EJ.

Psychiatr Serv. 2017 Jan 1;68(1):48-55. doi: 10.1176/appi.ps.201500290. Epub 2016 Aug 1.

36.

Some Additional Considerations Regarding the American Society of Addiction Medicine National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use.

Saxon AJ, McCance-Katz EF.

J Addict Med. 2016 May-Jun;10(3):140-2. doi: 10.1097/ADM.0000000000000219. No abstract available.

PMID:
27223833
37.

Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study.

Ling W, Hillhouse MP, Saxon AJ, Mooney LJ, Thomas CM, Ang A, Matthews AG, Hasson A, Annon J, Sparenborg S, Liu DS, McCormack J, Church S, Swafford W, Drexler K, Schuman C, Ross S, Wiest K, Korthuis PT, Lawson W, Brigham GS, Knox PC, Dawes M, Rotrosen J.

Addiction. 2016 Aug;111(8):1416-27. doi: 10.1111/add.13375. Epub 2016 Apr 21.

38.

Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial.

Hser YI, Evans E, Huang D, Weiss R, Saxon A, Carroll KM, Woody G, Liu D, Wakim P, Matthews AG, Hatch-Maillette M, Jelstrom E, Wiest K, McLaughlin P, Ling W.

Addiction. 2016 Apr;111(4):695-705. doi: 10.1111/add.13238. Epub 2016 Jan 13.

39.

Prevalence, Comorbidity, and Prognosis of Mental Health Among US Veterans.

Trivedi RB, Post EP, Sun H, Pomerantz A, Saxon AJ, Piette JD, Maynard C, Arnow B, Curtis I, Fihn SD, Nelson K.

Am J Public Health. 2015 Dec;105(12):2564-9. doi: 10.2105/AJPH.2015.302836. Epub 2015 Oct 16.

40.

Treatment outcomes in opioid dependent patients with different buprenorphine/naloxone induction dosing patterns and trajectories.

Jacobs P, Ang A, Hillhouse MP, Saxon AJ, Nielsen S, Wakim PG, Mai BE, Mooney LJ, S Potter J, Blaine JD.

Am J Addict. 2015 Oct;24(7):667-75. doi: 10.1111/ajad.12288. Epub 2015 Sep 24.

41.

Comparative safety of methadone and buprenorphine.

Saxon AJ.

Lancet Psychiatry. 2015 Oct;2(10):855-6. doi: 10.1016/S2215-0366(15)00413-7. Epub 2015 Sep 15. No abstract available.

PMID:
26384620
42.

Prevalence and Trends of Concurrent Opioid Analgesic and Benzodiazepine Use Among Veterans Affairs Patients with Post-traumatic Stress Disorder, 2003-2011.

Hawkins EJ, Malte CA, Grossbard JR, Saxon AJ.

Pain Med. 2015 Oct;16(10):1943-54. doi: 10.1111/pme.12787. Epub 2015 Sep 1.

PMID:
26332513
43.

CSF TNFα Has Not Been Shown to be Elevated in Headache Patients.

Saxon A.

Headache. 2015 Oct;55(9):1266. doi: 10.1111/head.12622. Epub 2015 Jul 21. No abstract available.

PMID:
26198734
44.

Cost-Effectiveness of Integrating Tobacco Cessation Into Post-Traumatic Stress Disorder Treatment.

Barnett PG, Jeffers A, Smith MW, Chow BK, McFall M, Saxon AJ.

Nicotine Tob Res. 2016 Mar;18(3):267-74. doi: 10.1093/ntr/ntv094. Epub 2015 May 4.

45.

A pilot trial of prazosin, an alpha-1 adrenergic antagonist, for comorbid alcohol dependence and posttraumatic stress disorder.

Simpson TL, Malte CA, Dietel B, Tell D, Pocock I, Lyons R, Varon D, Raskind M, Saxon AJ.

Alcohol Clin Exp Res. 2015 May;39(5):808-17. doi: 10.1111/acer.12703. Epub 2015 Apr 1.

46.

Risk Factors Associated with HCV Among Opioid-Dependent Patients in a Multisite Study.

Schulte M, Hser Y, Saxon A, Evans E, Li L, Huang D, Hillhouse M, Thomas C, Ling W.

J Community Health. 2015 Oct;40(5):940-7. doi: 10.1007/s10900-015-0016-2.

47.

Commentary on Burns et al. (2015): retention in buprenorphine treatment.

Saxon AJ.

Addiction. 2015 Apr;110(4):656-7. doi: 10.1111/add.12865. No abstract available.

48.

Quetiapine for the treatment of cocaine use disorder.

Tapp A, Wood AE, Kennedy A, Sylvers P, Kilzieh N, Saxon AJ.

Drug Alcohol Depend. 2015 Apr 1;149:18-24. doi: 10.1016/j.drugalcdep.2014.12.037. Epub 2015 Jan 27.

PMID:
25682480
49.

Tobacco use trajectories among a large cohort of treated smokers with posttraumatic stress disorder.

Malte CA, Dennis PA, Saxon AJ, McFall M, Carmody TP, Unger W, Beckham JC.

Addict Behav. 2015 Feb;41:238-46. doi: 10.1016/j.addbeh.2014.10.034. Epub 2014 Nov 4.

PMID:
25452071
50.

Medication-assisted therapy for opioid addiction.

Tai B, Saxon AJ, Ling W.

J Food Drug Anal. 2013 Dec;21(4):S13-S15.

Supplemental Content

Support Center